Elan appoints advisers over Tysabri

Elan has engaged Lehman Brothers to advise it following the announcement last Friday that Biogen has received expressions of …

Elan has engaged Lehman Brothers to advise it following the announcement last Friday that Biogen has received expressions of interest from potential purchasers.

The Irish pharmaceutical company and Biogen are joint stakeholders in the multiple sclerosis treatment Tysabri.

Elan said today that if Biogen was purchased, Elan has the right to acquire for fair value Biogen's economic interest in Tysabri under the terms of the collaboration agreement.

Elan said it may also restructure and continue the collaboration agreement with any potential purchaser.

Tysabri is being considered by the US Food and Drug Administration for use in the treatment of the gastro-intestinal condition Crohn's Disease.

  • Join The Irish Times on WhatsApp and stay up to date

  • Sign up for push alerts to get the best breaking news, analysis and comment delivered directly to your phone

  • Listen to In The News podcast daily for a deep dive on the stories that matter